Astellas Pharma Inc. has managed to win approval in one indication for its once-daily Astagraf XL (tacrolimus extended-release) for kidney transplant patients, several years after an initial filing that spanned three organs.
FDA approved the calcineurin inhibitor as a treatment to prevent organ rejection in kidney transplant patients on July 19. Astellas originally filed for FDA approval in 2005 in kidney, heart...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?